BiotechTube

UX007

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Conditions

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency

Trial Timeline

Feb 6, 2014 → Aug 25, 2016

NCT ID
NCT01886378

About UX007

UX007 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). The current trial status is completed. This product is registered under clinical trial identifier NCT01886378. Target conditions include Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02599961Phase 2Terminated
NCT02214160Phase 2Completed
NCT01886378Phase 2Completed

Competing Products

2 competing products in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

See all competitors
ProductCompanyStageHype Score
triheptanoinUltragenyx PharmaceuticalPre-clinical
18
TriheptanoinUltragenyx PharmaceuticalPhase 3
72

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved
80
GTX-102Phase 3
72
EvinacumabPhase 3
72
Adjuvant Immunomodulatory (IM) TherapyPhase 3
72
Oral prednisolone + Placebo for oral prednisolonePhase 3
72